TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

PONSTEL

MEFENAMIC ACID Cyclooxygenase Inhibitors
Immunology Approved 1967-03-28
1
Indication
--
Phase 3 Trials
58
Years on Market

Details

Status
Prescription
First Approved
1967-03-28
Routes
ORAL
Dosage Forms
CAPSULE

Companies

Active Ingredient: MEFENAMIC ACID

PONSTEL Approval History

Loading approval history...

What PONSTEL Treats

2 indications

PONSTEL is approved for 2 conditions since its original approval in 1967. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Pain
  • Dysmenorrhea
Source: FDA Label

PONSTEL Boxed Warning

RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. (see Warnings ). Mefenamic acid is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see Contraindications , Warnings ). G...

Drugs Similar to PONSTEL

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CATAFLAM
DICLOFENAC POTASSIUM
2 shared
AMICI PHARMA
Shared indications:
DysmenorrheaPain
DICLOFENAC POTASSIUM
DICLOFENAC POTASSIUM
2 shared
INGENUS PHARMS LLC
Shared indications:
DysmenorrheaPain
EC-NAPROSYN
NAPROXEN
2 shared
ATNAHS PHARMA US
Shared indications:
PainDysmenorrhea
NAPROSYN
NAPROXEN
2 shared
ATNAHS PHARMA US
Shared indications:
PainDysmenorrhea
ACUVAIL
KETOROLAC TROMETHAMINE
1 shared
AbbVie
Shared indications:
Pain
BELBUCA
BUPRENORPHINE HYDROCHLORIDE
1 shared
BDSI
Shared indications:
Pain
BUPRENORPHINE
BUPRENORPHINE
1 shared
WATSON LABS TEVA
Shared indications:
Pain
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
ASPIRIN
1 shared
STEVENS J
Shared indications:
Pain
BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE
1 shared
Hikma
Shared indications:
Pain
BUTORPHANOL TARTRATE PRESERVATIVE FREE
BUTORPHANOL TARTRATE
1 shared
Pfizer
Shared indications:
Pain
BUTRANS
BUPRENORPHINE
1 shared
PURDUE PHARMA LP
Shared indications:
Pain
BYQLOVI
CLOBETASOL PROPIONATE
1 shared
HARROW EYE
Shared indications:
Pain
CALDOLOR
IBUPROFEN
1 shared
CUMBERLAND PHARMS
Shared indications:
Pain
COMBOGESIC IV
ACETAMINOPHEN
1 shared
Hikma
Shared indications:
Pain
DIFLUNISAL
DIFLUNISAL
1 shared
Teva
Shared indications:
Pain
DIFLUPREDNATE
DIFLUPREDNATE
1 shared
Cipla
Shared indications:
Pain
DILAUDID
HYDROMORPHONE HYDROCHLORIDE
1 shared
Fresenius Kabi
Shared indications:
Pain
DUREZOL
DIFLUPREDNATE
1 shared
Novartis
Shared indications:
Pain
EXPAREL
BUPIVACAINE
1 shared
PACIRA PHARMS INC
Shared indications:
Pain
FLECTOR
DICLOFENAC EPOLAMINE
1 shared
IBSA
Shared indications:
Pain
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

PONSTEL FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Carefully consider the potential benefits and risks of mefenamic acid capsules and other treatment options before deciding to use mefenamic acid capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ; Gastrointestinal Bleeding, Ulceration, and Perforation ). Mefenamic acid capsules are indicated: For relief of mild to moderate pain in patients โ‰ฅ14 years of age, when therapy will not exceed one week (7 days). For treatment of primary dysmenorrhea.

โš ๏ธ BOXED WARNING

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur ...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.